Problem: Fluctuating hormones regulate reproductive processes in the female genital tract. Consequent changes in the local immunological environment are likely to affect cellular interaction with infectious agents and the assessment of therapies that target mucosal infections.
| INTRODUCTION
The female genital mucosa is home to cellular mediators of immunity such as Langerhans cells, CD4 + and CD8 + T cells, macrophages, dendritic cells, neutrophils, NK cells and B cells. 1 These cells mediate the innate and adaptive components of mucosal immunity often via the production of a plethora of chemokines, cytokines and other immunoproteins. CD4 + T cells expressing receptors like CD4 and CCR5 also constitute targets for infectious viral particles that traverse the epithelial barrier. 2 Layers of intact stratified squamous cells line the vagina and ectocervix, whilst the single columnar epithelium maintains the integrity of the endometrium and endocervix. 2 Together these cells in the most exposed regions of the female genital tract provide a reasonable physical barrier to the entry of infectious pathogens like HIV and an additional secretory mucosal component containing amongst other things innate antimicrobial proteins like secretory leucocyte protease inhibitor (SLPI) 3 and defensins. 4 Varying levels of endogenous female hormones like oestradiol and progesterone regulate the onset of ovulation, implantation, menstruation and other reproductive processes in the female genital tract.
5
These hormones are also known to induce changes in the appearance and function of mucosal tissue. For instance, over the course of the menstrual cycle hormonal fluctuations are believed to induce changes in the viscosity of the secretory component of the mucosal environment. 6 The epithelial barrier is also reportedly affected by these changes as evidenced in the progesterone-induced thinning observed in macaques. 7 These changes have been shown to increase tissue susceptibility to simian immunodeficiency virus (SIV) and are likely to affect HIV infection, 8 as well as the uptake and response to vaccines and topical microbicides. Although absolute numbers of the immune cells are believed to fluctuate across the menstrual cycle, 9 phenotypic changes and consequent variations in the levels of secreted chemokines, cytokines and immunoproteins in the periphery and in mucosal tissue have not been fully elucidated. There is some evidence to show that the concentrations of immunoproteins in the mucosal compartment vary with the menstrual cycle. 10 A recent study of cervicovaginal secretions obtained from Tanzanian women considered to be at high risk of HIV demonstrated increases in a number of mucosal analytes from pre-to post-ovulation phases of the menstrual cycle. 11 Such significant variations in the levels of secreted immunoproteins over the menstrual cycle particularly if they are unique to the mucosal compartment are likely to affect the outcome and monitoring of therapies that target the mucosal compartment, thus making a case for the consideration of these differences in the evaluation of mucosal infections in general and in clinical studies aimed at designing or assessing interventions against HIV infection.
Identifying the best sampling approach for evaluating mucosal responses to infection and therapy has been a priority, not only for HIV vaccine development, but also for the evaluation of microbicides. 12, 13 Sample quality, ease of collection, processing and downstream analyses are common factors considered in selecting the appropriate approach. In this study, we assessed the levels of 39 different soluble immunoproteins in secreted samples collected from the cervicovaginal compartment and compared them with those in the endocervix collected at a single time point corresponding to the follicular phase. In doing so, we provide a direct comparison of 2 important mucosal sampling techniques. We also collected secretions from the cervicovaginal compartment at 3 distinct points that correspond with the follicular (proliferative), ovulatory and luteal (secretory) phases of the menstrual cycle and compared them with levels seen in the peripheral compartment (serum) at the corresponding time points. Analytes assessed include cytokines, growth factors, chemokines, antimicrobial (including antiviral) proteins and immunoglobulins. We produced profiles of the immunological landscape across the menstrual cycle highlighting critical points that need to be considered in designing and assessing mucosal interventions against pathogens like HIV.
| METHODS

| Study design and ethical approval
The CASHIR (characterization of the activity and stability of anti-HIV-1 agents in the presence of female genital secretions and establishing methods to measure immune response) study was initiated to help in the development of novel agents against mucosal infections such as HIV. Its main aim was to provide some clarity on reliable methods used to measure immune responses in the female genital tract.
As such, it was designed as a longitudinal prospective cohort study to enable the standardization and comparison of methods and sampling approaches. We set out to explore the measurement of cytokine, chemokine and antibody responses in cervical/vaginal secretions and serum, taking into cognizance the effect of the menstrual cycle on these factors. Samples were collected at The Vaccine Institute, St
George's University of London. All volunteers gave full informed and written consent. All relevant approvals were in place, and the study was conducted in accordance with the relevant Clinical Regulations and guidelines on Good Clinical Practice.
| Subjects and sample collection protocol
Screening was focused on healthy female volunteers aged 18- 
| Processing of samples for immunological assays
Prior to immunological analysis, serum sample aliquots were heat inactivated at 56°C with slow mixing for 35 minutes. Softcups containing secretions in 50 mL collection tubes were removed from −80°C, allowed to thaw on ice and centrifuged at 400 g for 15 minutes at
4°C. An equal volume of extraction buffer was then added to the secretion samples (after removal of the cup) with mixing. Processed aliquots were then used in immunological assays or frozen at −80°C.
Similarly Spin-X tubes containing Weck-Cel ® spears (sponges) were thawed on ice, centrifuged at 13 800 g in a microcentrifuge at 4°C.
300 μL extraction buffer was added to the top chamber of the Spin-X tube containing the spears centrifuged again for an additional 15 minutes at 13 800 g and 4°C to further extract any residual secretions.
Sponges were removed and eluates used in assays or aliquoted for storage at −80°C.
| Measurement of immunological proteins
Thirty-three soluble immune proteins were quantified in all processed samples using an in-house Luminex assay comprising of 4 panels. Bio-Rad Laboratories Ltd., (Hertfordshire, UK). In all cases, a set of standard curves were run on each plate. Analytes were quantified using Bio-Plex ® 100 Luminex analyzer (Bio-rad Laboratories). Data were collected for 3 replicates per sample using Bio-Plex Manager Software version 6 (Bio-Rad Laboratories Ltd). A five-parameter logistic regression formula was used to derive sample concentrations from the standard curves. Analytes below the lower limit of detection were assigned a concentration of half the lower limit of quantification (LLOQ).
| Statistical analysis
Data were characterized using a range of statistical methods. We did not assume a normal distribution for analyte concentrations in our population. The comparison of analyte concentrations in paired samples collected from various compartments was performed using the nonparametric Wilcoxon matched-pairs signed ranked test. The same method was applied to the evaluation of analyte fluctuations in each compartment over the menstrual cycle. Spearman correlation was used to calculate the relationships between analyte sampling techniques and compartmental secretions. P-values were generally considered not significant at ≥.05. All statistical analyses were performed and graphs drawn using GraphPad Prism 6 Software.
| RESULTS
| Characteristics of participants
Although samples were collected from 31 women during the course of the study, 19 participants were excluded on account of the F I G U R E 1 Illustration of the timeline for study visits with a list of the localized analyte changes occurring in the mucosal compartment. Phases of the menstrual cycle were specified for volunteers as the number of days since their last menstrual period where day 1 coincided with the first day of their menses. Samples were collected during 3 scheduled visits coinciding with days 5-10 (end of menstruation; follicular phase), days 14-16 (ovulation) and days 19-24 (luteal phase).
More analyte fluctuations were recorded in study subjects over the time points that were investigated in the mucosal compartment compared to the serum compartment participants not being available for sampling across all the time points (Figure 1 ), or not providing matching samples from all sampled compartments for comparison. Of the analysed participants, 4 were on combined oral contraception, and one was on combined transdermal contraception whilst the rest of the analysed participants used barrier contraception (condoms). Participants were between the ages of 18 and 45 years with a median age of 27 years.
| Endocervical and cervicovaginal compartments display distinctive immunological analyte signatures in the follicular phase of the menstrual cycle
Samples were collected from 2 compartments at visit 1 corresponding to days 5-10 of the menstrual cycle from study participants. We measured the concentrations of 39 analytes in the samples collected from the cervical os representing endocervical secretions or the upper vaginal region using Weck-Cel ® spears or an Instead ® Softcup, respectively. We found the analyte signatures to be similar overall ( Figure 2A ) with strong correlations (r = .96; P = .0001) ( Figure 2B ).
However, there were significant differences between the 2 compartments with regard to a few analytes. Although the average analyte concentrations were generally higher in the vaginal samples, we observed significantly higher concentrations in 6/39 analytes (IL-6, P = .0137; IFN-β, P = .0005; SLPI, P = .0005; MIP-3α, P = .0010; Pselectin, =.0005; and G-CSF, P = .0244) in the samples collected by direct adsorption from the cervical os with Weck-Cel ® spears (Table   S1 ). Notably, there were no significant differences in the concentrations of mucosal antibodies (IgG1-4, IgA or IgM) recorded using both sampling techniques. Due to the observed correlation between the analyte signatures obtained using both techniques, we opted to use Softcups in subsequent analysis as it was generally considered to be more acceptable and less invasive for study participants.
| Serum and cervicovaginal compartments display distinctive immunological analyte signatures across the menstrual cycle
We compared analyte concentrations in the samples obtained from the upper vaginal region with those seen in the serum compartment and found the signature of each compartment to be distinct at visit 1 ( Figure 3 and Table 1 ). The differences in analyte concentrations in both compartments were significant for 29/39 analytes at visit 1 (Table 1) . Of the 29 analytes that were found to be different, We recorded significant differences in just 3/39 (SLPI, P-selectin and IL-7) analytes in the serum compartment (Figures 4 and S2 ) across the menstrual cycle with all but IL-7 increasing with cycle progression.
Fluctuations in serum analyte concentrations across the cycle were significant for analytes belonging to 3 functional groups (Haemopoietic/growth factors, antimicrobial and cell homing). Immunoglobulin levels remained largely stable in the serum compartment throughout the cycle. Notably, there was no overlap between the analytes that were seen to vary across the menstrual cycle in the serum and vaginal compartments ( Figure S2 ). require sample dilution at the point of collection. 14 However, both methods are not necessarily optimal for volume standardization and ease of sample collection. In studies comparing sampling of mucosal secretions using swabs or CVL, the latter resulted in higher concentrations of immunoproteins despite the extensive dilution of samples that occurred during CVL sample collection. 13 Another study looking at cell recoveries for mucosal sampling techniques noted that the CVL approach enabled the recovery of the lowest amount of viable mononuclear leucocytes in comparison with collection with cytobrushes or biopsies. 18 Softcups rank high in user acceptability 12 and have become increasingly popular due to the practical advantages of their use by study participants without the need for clinical personnel, and possibility of obtaining cervicovaginal secretions as a concentrate without dilution leading to better detection of analytes in comparison with CVL. 14 We sought to determine whether differences exist in the secreted analyte signatures observed using 2 sampling methodologies that have not been compared directly before. Whereas previous studies have highlighted the need to consider differences that may arise as a result of methodology or the location of sampling in the genital tract, 13, 14, 19 we found strong correlations between the secreted analyte signatures observed in samples collected and eluted from Weck-Cel ® sponges and those collected using Softcups.
| DISCUSSION
However, analyte concentrations were distinctly higher in the samples collected using the Softcups. The latter observation is in agreement with a previous study comparing Softcups with CVL sampling. Wilcoxon matched-pairs signed rank test applied to values recorded for study subjects at visit 1 with P values <.05 considered to be significant.
The bold values serve to draw the attention of the reader to the values for which differences observed are statistically significant. In this study, we have measured 39 analytes to provide a picture of how they vary in the mucosal versus peripheral compartment and across the menstrual cycle. In doing so, we also provide a comparison of key mucosal sampling methods to inform therapeutic research. The limitations of this study include the small sample size and the absence of a direct quantification of hormone levels in study participants. However, we reasoned that samples collected at visits 1 and 3 in normal cycling women would enable us to compare the immunological profiles at the peak of oestrogen and progesterone release, respectively. In addition, we have not adjusted our findings to reflect any difference that may arise from reported behaviours described in the methods section such as the use of oral contraception, or unreported/undiagnosed infections in volunteers. It is also worth pointing out that 4 of the participants in this study were on oral combined contraception whilst one was on combined transdermal contraception even though they all had regular withdrawal bleeding.
Nevertheless, our data highlight the need to standardize the timing of mucosal sampling in clinical studies. One approach could be to ensure that sampling in all study participants occurs within a similar period of the menstrual cycle to ensure that the differences in local cyclical effects are minimized. A similar advantage would be applicable if the administration and assessment of therapies are designed to fall within similar periods within the menstrual cycle. As an example, the period defined by visits 2-3 of our study showed the least amount There is currently a need to design and evaluate vaccines that are capable of eliciting protective mucosal immunological responses that can prevent HIV acquisition and transmission, [39] [40] [41] particularly in women 2 who have been reported to be more susceptible to infection compared to age-matched males. 42 Indeed, a number of studies have evaluated aspects of this approach such as the linkage between the nasal and genital mucosal compartments, 43 and the quality of the responses that are elicited by various antigens and delivery methods.
44,45
None of these studies have taken into account the role that the unique and dynamic cervicovaginal immunological landscape might have on the outcome of vaccine regimens. Our data demonstrate the need to fully consider this in the design and execution of future vaccine studies.
